OBJECTIVES The aim of this study was to assess safety outcomes of femoropopliteal drug-coated balloon (DCB) angioplasty using patient-level data from the Lutonix clinical program.
L ower extremity peripheral artery disease (PAD) is an increasingly prevalent global health concern, associated with a 3-to 5-fold increase in mortality risk over that of the general population (1, 2) . Although endovascular or open surgical revascularization is recommended for patients with symptomatic femoropopliteal PAD, there remains no consensus on the optimal strategy for this patient population (3) . proportional hazards modeling was used to identify predictors of time to adverse events, time to serious adverse events (SAEs), and time to death.
RESULTS

DEMOGRAPHIC AND BASELINE CHARACTERISTICS.
The demographic and baseline characteristics were comparable in patients treated with DCB angioplasty and PTA in the LEVANT trials ( Table 2) . Patients in the LEVANT 2 study were largely men (DCB angioplasty, 61.1%; PTA, 66.9%), and the most common comorbidities were hypertension, dyslipidemia, and myocardial infarction. Approximately 80% of DCB and PTA patients were current or former smokers.
The average target lesion length was 62.1 AE 41.6 mm in the DCB group and 62.3 AE 40.9 mm in the PTA group ( Table 3) . Most target lesions were de novo (DCB, 87.7%; PTA, 91.9%), and calcification was re- Ouriel et al. finding that persisted through 5-year follow-up (8, 11) .
A study of Medicare beneficiaries also found no differences in mortality in patients with PAD treated with DES or bare-metal stents (4) .
The systematic review and meta-analysis of Kat- Reintervention itself was protective against mortality. Irrespective of whether patients were in the DCB or the PTA randomized treatment arm, they were less likely to die if they underwent reintervention.
The same finding was noted with paclitaxel reinterventions; reintervention with paclitaxel-containing devices was protective against mortality whether a patient was in the DCB or PTA randomized treatment arm. 
